With the legalization of cannabis it has become essential to establish a sound scientific basis for its therapeutic use. There have been a number of claims that cannabis benefits many conditions; however, these reports are of dubious value since they are often anecdotal and frequently contradictory. The tests that form the basis of these claims lack standardization, using a wide variety of animals, methods and ways of reporting results. While some experiments have been done on isolated compounds such as THC, most use extracts from the whole plant where the chemical composition is largely undefined. There are a vast number of compounds (over 80 cannabinoids) within cannabis plants and a tremendous variation in the chemical composition of various cultivars - plants selected for desirable characteristics that can be maintained by propagation. It is likely that the therapeutic actions of whole plant extracts are better than the individual components. Therefore, we will investigate existing cultivars and create new cultivars with different profiles.
Cannevert's research plan includes using modern analytical techniques to obtain a chemical profile of individual cultivars, and administering the profiled cultivars to animals to identify their ability to treat disease conditions. This allows us to establish a therapeutic profile and associated side effects for chronic and disabling conditions such as pain, nausea and vomiting, depression and anxiety. Our goal is to effectively treat these conditions while avoiding severe adverse effects such as analgesic addiction. Laboratory experimentation is a key step for the development of drugs to be used clinically. Because the organs and systems in animals are similar to humans, our test results will likely translate to human outcomes. We use a battery of well-established experimental models, including standard, whole animal and cultured cell assays. By correlating chemical and therapeutic profiles, we can establish the scientific basis for the clinical use of medical cannabis and reveal the ability of individual cultivars to treat disease. Ongoing and future clinical trials based on our data may lead to improved treatment for many chronic health problems.
Cannevert Therapeutics was established for the specific purpose of releasing the therapeutic potential of different cannabis cultivars in a clear, systematic and scientific manner. The company was founded by and consists of a group of academic scientists, many who have spent years as professors in the UBC Faculty of Medicine, as well as experienced PhD scientists and technical personnel. Our team members have a wide range of relevant experience in chemistry and pharmacology, with particular expertise in human clinical trials. Our members also have an extensive track record with starting and running biotech companies, including the public companies Cardiome Pharma Corp. (CRME –NADSDAQ, COM-TSE) and Verona Pharma PLC (VRP - AIM, London), and the private biotech companies Magic Bullets Enterprises Ltd. and Pneumolabs UK Ltd. – all dedicated to drug discovery. Thus, we have over 150 years of collective experience in drug discovery and drug-related studies with a direct relationship to Cannevert's mandate: to establish a sound scientific foundation for the therapeutic use of cannabis.